Defibrillation threshold (DFT) testing has been an integral part of implantable cardioverter-defibrillator (ICD) implantation to confirm appropriate sensing of ventricular fibrillation and to establish an adequate safety margin for defibrillation. However, there is a lack of evidence regarding benefits of routine DFT testing. Therefore, we performed a meta-analysis to assess its mortality benefit. We searched MEDLINE for studies comparing mortality outcomes in ICD recipients who underwent DFT testing to those who did not. For the second analysis, studies comparing outcomes in patients with high-vs low-energy DFT were included. Odds ratio and standard errors were calculated, and inverse variance method in a random-effect model was used to combine effect sizes. Fifteen studies with 10,975 subjects comparing outcomes in patients who underwent routine DFT testing during ICD implantation and those who did not were included. There was no difference in the group that did not undergo DFT testing with regards to all-cause mortality (OR 0.935; CI 0.725-1.207; P = 0.606), cardiac mortality (OR 0.709; CI 0.385-1.307; P = 0.271), noncardiac mortality (OR 0.921; CI 0.701-1.210; P = 0.554), and arrhythmic mortality (OR 1.152; CI 0.831-1.596; P = 0.396). Percentage of successful appropriate first shocks among the two groups showed no difference. Five studies with 2278 subjects were included in the second analysis comparing patients with low DFT vs high DFT. Patients with high DFT had no significant increase in all-cause mortality compared to patients with low DFT (OR 0.527; CI 0.034-8.107; P = 0.646). Patients requiring higher DFT had no increased all-cause mortality compared to patients with lower DFT. Routine DFT testing during ICD implantation does not confer any significant benefit.
| Inclusion criteria

For meta-analysis comparing mortality in DFT testing vs No DFT
testing: Studies (retrospective and prospective; randomized and nonrandomized) comparing outcomes in patients who received DFT testing to patients who did not receive DFT testing at the time of implant of their ICD, CRT-D, or upgrade were included, if they reported incidence of all-cause, cardiac, noncardiac, and/or arrhythmic mortality. Studies with a mean follow-up duration of at least 12 months to assess mortality were included.
For the secondary meta-analysis comparing mortality in high DFT at testing vs low DFT at testing: Studies of patients undergoing DFT
testing prior to ICD implantation were included, if they reported the incidence of all-cause mortality and compared it between patients requiring high DFT at testing vs low DFT at testing. The arbitrary cutoff for labeling high DFT vs low DFT varied among individual studies with values ranging from 9 to 18 Joules (J) ( Table 2 ).
| Exclusion criteria
Studies were excluded if they (a) lacked a control group, (b) inadequate data on baseline characteristics, (c) were published only in abstract form, and (d) were non-English studies with no English translation.
| Search strategies
We searched MEDLINE and Google Scholar using keywords: defibrillation threshold testing, DFT, ICD, implantable cardiac defibrillator, AND mortality, in various combinations. "Related Article" was featured on PubMed, and a manual search of references was also used to identify additional studies. We reviewed the full text of relevant articles. English translations, if necessary, were obtained. Titles and abstracts were independently reviewed by two reviewers (M.A and N.T) and cross-verified for inclusion. Details of the search strategy are reported in Figure 1. 
| Data extraction and assessment of study quality
For each included study, all data elements uniformly reported across most studies were extracted by a third reviewer (M.K) and are shown in Tables 1 and 2 . The quality of each study was evaluated in accordance with the guidelines of United States Preventive Task Force and the Evidence-Based Management Group. 16, 17 The follow- "poor" if they met 3 or less criteria, "fair" if they met 4-5 criteria, and "good" if they met >5 criteria. The quality assessment of individual studies is reported alongside baseline variables in Tables 1   and 2 . All disagreements between reviewers were resolved by consensus.
| Statistical methods
Data were extracted as either odds ratio (OR) or event rate. If hazard ratio was available, it was considered as the best estimate of OR. If both univariate and multivariate analyses were available, data from multivariate analyses were taken. Pooled ORs and 95% confidence intervals (CIs) were calculated using the more conservative
DerSimonian and Laird random-effects model. 18 All tests were 2-sided, and a P value <0.05 was deemed significant. Heterogeneity was assessed by the I 2 statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than chance. I 2 > 50% was considered significant heterogeneity. 19, 20 Potential publication bias was assessed by visual inspection of funnel plots, in which standard errors were plotted against log ORs, as well as Eggers regression intercept. All statistical analyses were performed using Comprehensive Meta-Analysis V3 (BioStat Inc., Englewood, NJ).
| RESULTS
| Meta-analysis of DFT Testing vs No DFT Testing
Fifteen studies with 10 975 subjects comparing outcomes in patients who underwent routine DFT testing during ICD/CRT-D implantation and those who did not were included in the primary meta-analysis.
Eight studies were retrospective cohort, while remaining seven were prospective with four randomized controlled trials (RCT). Baseline characteristics of the studies included in the primary analysis are shown in Table 1 .
The average mean follow-up duration of the studies was | 601 device.
Step
. Three studies 13, 38, 39 included patients with hypertrophic cardiomyopathy, while only one study 38 included patients with congenital heart disease. Analysis of the funnel plot for the primary analysis showed no significant publication bias ( Figure 1A ). In our pooled analysis (Figure 2) , we found that patients who did not undergo routine DFT testing prior to ICD implantation had no significant increase in all-cause mortality compared to the patient group that did undergo DFT testing (OR 0.935; CI 0.725- 
| Meta-analysis of high DFT vs low DFT
Five studies with 2278 subjects were included in the second analysis comparing patients with low DFT at the time of testing vs high DFT.
Three studies were retrospective, and two were prospective. Baseline study characteristics are shown in Table 2 . Follow-up duration ranged from 6 to 60 months. Individual studies had their own cutoff values for segregating high DFT vs low DFT groups with values ranging from 9 to 18 J ( Table 2) . Roman-Gonzalez et al 22 is the only study that had its high DFT group labeled as those requiring DFT >25 J along with defibrillation safety margin (DSM) <10 J. Funnel plot for the analysis showed no significant publication bias among the studies ( Figure 3A ). Our pooled analysis ( Figure 6 ) showed that patients with high DFT at testing had no significant increase in allcause mortality compared to patients with low DFT (OR 0.527; CI 0.034-8.107; P = 0.646).
| DISCUSSION
Our meta-analysis of published prospective and retrospective data shows that patients who did not undergo routine DFT testing during ICD implantation have no evidence of increased all-cause, cardiac, or arrhythmic mortality compared to patients who underwent DFT testing. The results of our analysis that includes two additional studies including a large RCT are consistent with recently published meta-analysis 23 and recent randomized controlled trials 13, 14 ; wherein, no difference in cardiac mortality was detected. Our meta-analysis also shows for the first time that patients with high DFT at implantation testing have similar outcomes as patients with low DFT. | 603
center's practice. 27 Furthermore, antiarrhythmic drugs and electrolyte imbalance have shown to influence DFT, making usefulness of routine testing even more challenging. In several previous studies, untested patients appeared to be sicker at baseline than tested patients and may have created a selection bias in the assessment of outcomes of the untested patient groups. 9, 12, 28 Some experts have also argued that performing DFT testing is unlikely to reduce sudden cardiac death rate to a value that is clinically relevant (<1%). 11 The reasons for the failure of DFT testing to actually show any improvement in clinical outcomes and mortality are not clear and only speculated at this moment. One common explanation is that ICD shocks per se can lead to adverse cardiovascular outcomes 24 which may counteract any potential benefit of DFT testing. A recent investigation shows that DFT testing is associated with elevated plasma levels of troponin, NT Pro BNP, and markers of apoptosis. 29 This periprocedural acute myocardial damage triggered by DFT test shocks can further be detrimental if more than one shock is required to terminate induced ventricular fibrillation. It is important to note that time interval between these test shocks may be relevant for defibrillation thresholds and any correlation with cardiac damage and overall prognosis needs to be further investigated. Although uncommon, DFT testing has been known to be associated with complications including hemodynamic compromise, stroke, nonresponsive ventricular fibrillation, need for resuscitation, and death. 9, 30, 31 Another reasoning is that DFT testing under controlled conditions may not replicate the patient's condition during a ventricular arrhythmia (congestive heart failure, ischemia, and electrolyte imbalance) and hence may not be a reliable predictor of outcome. 10 While an argument may be made that even with the current technology, a significant number of patients identifiable by risk scoring systems 32 have high DFT at implantation, 33 given that defibrillation is a probabilistic phenomenon, 34 baseline DFT testing does not have any predictive value on the future shock efficacy. 35 Similar results were found in our study as well where the percentage of successful appropriate first shocks did not differ between groups that underwent DFT testing and did not undergo DFT testing (OR 0.611; CI 0.349-1.070; P = 0.948). There is a paucity of evidence regarding routine DFT testing in patients with hypertrophic cardiomyopathy and congenital heart disease, and the results are contradicting. [51] [52] [53] [54] As studies included in this meta-analysis did not have adequate representation of patients with hypertrophic cardiomyopathy and congenital heart disease, it may not be unreasonable to consider DFT testing at the time of ICD implantation in these patients. Nonetheless, the question of whether this particular subset of patients gets any benefit from DFT testing needs to be evaluated by appropriately powered randomized trials.
High DFT at the time of implantation, while associated with a more sicker patient population, may not always be associated with F I G U R E 5 Forest plot of arrhythmic mortality in patients who underwent DFT testing compared to those who did not F I G U R E 6 Forest plot of all-cause mortality in patients who had high DFT at testing compared to those who had low DFT increased mortality or an increased risk of sudden death.
